ChartMill · Oct 23, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA): High Growth Momentum Meets a Breakout Setup
KNSA pairs high growth momentum with a strong technical breakout setup, but its Setup Rating only meets the screen’s threshold.
KN
NASDAQ · KNSA
Kiniksa Pharmaceuticals, Ltd.
Healthcare · Biotechnology
$92.24
Down-$5.32 (-5.45%)
Updated Nov 1, 2026, 9:39 PM
SID Score
6.0/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 3B
- P/E ratio
- 83.96
- Dividend yield
- 0.00%
- 52-week range
- $36.56 – $98.48
- Volume
- 1.32M
- Avg. volume
- 427.35K
Price performance · KNSA
KNSA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
KNSA closed at $92.24 after 20 trading sessions, up 20.88% for the selected period.
- Last close
- $92.24
- Period change
- +20.88%
- Period low
- $72.98
- Period high
- $97.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $97.40 | $98.48 | $91.25 | $92.24 | 1.32M |
| Oct 29, 2026 | $95.00 | $98.355 | $94.40 | $97.56 | 1.38M |
| Oct 28, 2026 | $87.875 | $95.28 | $87.54 | $95.18 | 1.71M |
| Oct 27, 2026 | $85.00 | $90.80 | $82.26 | $89.20 | 2.32M |
| Oct 26, 2026 | $75.995 | $76.48 | $70.67 | $72.98 | 1.43M |
| Oct 23, 2026 | $80.16 | $80.22 | $76.58 | $76.73 | 576.56K |
| Oct 22, 2026 | $79.32 | $81.30 | $78.3892 | $80.79 | 429.71K |
| Oct 21, 2026 | $83.41 | $84.06 | $78.74 | $79.70 | 838.63K |
| Oct 20, 2026 | $80.25 | $83.78 | $79.88 | $83.17 | 1.24M |
| Oct 19, 2026 | $78.78 | $80.61 | $78.3601 | $79.48 | 602.15K |
| Oct 16, 2026 | $79.94 | $80.34 | $76.88 | $78.59 | 525.19K |
| Oct 15, 2026 | $79.85 | $82.979 | $79.62 | $79.94 | 1.49M |
| Oct 14, 2026 | $78.115 | $79.96 | $77.70 | $78.84 | 576.56K |
| Oct 13, 2026 | $79.21 | $80.00 | $78.45 | $78.53 | 578.48K |
| Oct 12, 2026 | $80.00 | $80.9899 | $78.82 | $79.24 | 340.94K |
| Oct 9, 2026 | $78.24 | $80.50 | $78.03 | $79.78 | 430.28K |
| Oct 8, 2026 | $77.18 | $78.83 | $75.44 | $78.75 | 411.57K |
| Oct 7, 2026 | $76.18 | $79.22 | $74.70 | $77.96 | 381.05K |
| Oct 6, 2026 | $76.00 | $77.32 | $73.84 | $77.09 | 378.74K |
| Oct 5, 2026 | $75.97 | $76.79 | $75.285 | $76.31 | 391.51K |
Latest KNSA news
The latest Smart Investors Daily articles mentioning KNSA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KNSA research
Overview
Company profile and research snapshot.
Company profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $51.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | JP Morgan | Overweight | — |
| Oct 28, 2026 | Goldman Sachs | Buy | — |
| Oct 28, 2026 | Wells Fargo | Overweight | — |
| Oct 28, 2026 | Wedbush | Outperform | — |
| Jul 30, 2026 | Goldman Sachs | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may regist
Yahoo · Oct 14, 2026
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.
ChartMill · Oct 13, 2026
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs Strong Growth With a High-Quality Technical Setup
Kiniksa Pharmaceuticals shows strong growth, profitability, and a bullish technical setup, making KNSA a compelling biotech breakout candidate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
